Enorama Pharma AB (OSTO:ERMA) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:ERMA Enorama Pharma AB OSTO:ERMA
29 GF Score
Price kr0.34
GF Value kr0.40
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Enorama Pharma AB Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

OSTO:ERMA
29GF Score
Enorama Pharma AB OSTO:ERMA
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Enorama Pharma AB (OSTO:ERMA) Overvalued in 2026?

Based on GuruFocus' analysis, Enorama Pharma AB stock appears to be undervalued. The current stock price of kr0.34 is trading 15.8% below its estimated GF Value™ of kr0.40. GuruFocus considers Enorama Pharma AB to be Modestly Undervalued.

Key valuation signals for OSTO:ERMA:

  • Interest Received:
  • GF Value™: kr0.40 vs. price of kr0.34 (15.8% below fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the OSTO:ERMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Enorama Pharma AB Business Description

Address Vastra Varvsgatan 19, Malmo, SWE, SE-211 77
Enorama Pharma AB is a pharmaceutical company that focuses on consumer-friendly medicated chewing gum containing generic substances. It provides medicated gums containing generic pharmaceutical substances, developed through its ChewMed technology platform.
29GF Score

Get the complete analysis for OSTO:ERMA

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.34
Price
kr0.40
GF Value